You might also like
Azenta, Inc. is a global leader in life sciences solutions, specializing in the management and exploration of biological and chemical compound samples. The company supports pharmaceutical, biotechnology, academic, and healthcare institutions by providing innovative products and services that enable faster development of therapies and scientific breakthroughs. Azenta's offerings include sample management systems, genomic services, and cold-chain solutions, catering to the growing needs of the life sciences industry.
-
Sample Management Solutions (SMS) - Provides end-to-end sample management products and services, including automated storage systems, cryogenic systems, sample consumables, and repository solutions to ensure sample quality, security, and integrity throughout their lifecycle.
- Sample Repository Solutions (SRS) - Offers comprehensive storage and management of biological samples.
- Core Products - Includes automated stores, cryogenic systems, automated sample tubes, and consumables and instruments.
-
Multiomics - Delivers genomics services such as gene sequencing, synthesis, and editing, supporting research in areas like cell and gene therapy, antibody development, and biomarker discovery.
-
B Medical Systems - Specializes in temperature-controlled storage and transportation solutions for cold chain management, including vaccine storage and transport systems.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
David Wang Executive | Senior Vice President and General Manager, Sample Management Solutions (SMS) | None | Leads SMS business; previously held roles at McKinsey, Johnson & Johnson, and PerkinElmer. | |
Dr. Ginger Zhou Executive | Senior Vice President and General Manager, Multiomics | None | Leads Multiomics business; joined Azenta in 2018 and has a Ph.D. in Molecular Biology and Biochemistry. | |
Jason W. Joseph Executive | Senior Vice President, General Counsel, and Secretary | None | Oversees legal affairs, corporate governance, and compliance; joined Azenta in 2011 and promoted to SVP in 2017. | |
John P. Marotta Executive | President and Chief Executive Officer (CEO) | None | Extensive experience in life sciences and healthcare; previously CEO of PHC Holdings Corporation; joined Azenta in 2024. | View Report → |
Lawrence Lin Executive | Executive Vice President and Chief Financial Officer (CFO) | None | Finance leader with expertise in business systems and lean principles; previously CFO at GeoStabilization International LLC. | |
Olga Pirogova Executive | Senior Vice President and Chief Human Resources Officer (CHRO) | None | Leads HR strategy; previously CHRO at Speedcast and held leadership roles at BD (Becton, Dickinson & Company). | |
Violetta Hughes Executive | Vice President, Chief Accounting Officer, and Principal Accounting Officer | None | Oversees financial accounting and reporting; previously SVP and CAO at Akebia Therapeutics. | |
Alan J. Malus Board | Director | None | Former Corporate EVP at Thermo Fisher; extensive experience in life sciences and diagnostics. | |
Didier Hirsch Board | Nominee for Director and Chair of the Audit Committee | Board Member at Knowles Corporation and Sophia Genetics SA | Former CFO of Agilent Technologies; expertise in financial management and governance. | |
Dr. Martin Madaus Board | Director | Board Member at Repligen Corporation, Quanterix Corporation, and Standard BioTools Inc.; Senior Operating Executive at The Carlyle Group | Former CEO of Millipore Corporation; expertise in life sciences and diagnostics. | |
Erica J. McLaughlin Board | Director and Chair of the ESG Committee | EVP, CFO, and Head of Corporate Strategy at Cabot Corporation; Member of FM Global New York Advisory Board | Financial expert with experience in ESG, mergers, and acquisitions; CFO at Cabot Corporation. | |
Frank E. Casal Board | Chair of the Board of Directors | None | Former Vice Chair of Audit at KPMG LLP; joined Azenta's Board in 2021 and became Chair in 2024. | |
Michael Rosenblatt Board | Director | Director at Rubius Therapeutics; Senior Advisor at Flagship Pioneering and Bain Capital Life Sciences | Former EVP and CMO at Merck; extensive experience in healthcare and life sciences. | |
Quentin Koffey Board | Director | Founder and Managing Partner at Politan Capital Management; Director at Masimo Corporation (NASDAQ: MASI) | Investment expert with a focus on capital allocation and governance; founder of Politan Capital Management. | |
Robyn C. Davis Board | Director and Chair of the Finance Committee | Corporate Director at Psychemedics Corporation (NASDAQ: PMD); Director at Akston Biosciences, LLC | Managing Director of AngelHealthcare Investors; expertise in growth strategy and leadership development. | |
Tina S. Nova Board | Director | Director at Exagen, Inc. (NASDAQ: XGN) | Industry veteran in life sciences; expertise in IPOs, mergers, and acquisitions. | |
William L. Cornog Board | Director and Chair of the Value Creation Committee | Board Member at Brightview Holdings Inc. (NYSE: BV) and LiveWire (NYSE: LVWR) | Former head of KKR Capstone; expertise in portfolio management and value creation. |
- Your guidance for the Multiomics segment remains at low single-digit growth despite achieving 11% growth in NGS this quarter; what factors are causing you to anticipate a deceleration in growth for the remainder of the year?
- Despite your confidence in the SMS backlog and pipeline, large stores revenue was down 13% this quarter; is this decline purely due to timing, or are you observing underlying customer cautiousness that could impact your mid-single-digit growth guidance for SMS?
- Given the 11% year-over-year decline in Sanger Sequencing revenue due to shifts in sequencing technology, how do you plan to address these headwinds and offset the declines within the Multiomics segment?
- With the sale process of B Medical Systems still in the initial stages, how might this extended timeline affect your strategic initiatives and capital allocation priorities, and what steps are you taking to ensure it doesn't hinder value creation?
- You have undertaken restructuring to rightsize your G&A cost structure and improve margins; can you provide more details on the expected cost savings, any associated one-time charges, and how these changes might impact your ability to invest in growth initiatives?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Hamilton Company | A main competitor in the Sample Management Solutions segment, specifically for automation systems. |
Liconic AG | A main competitor in the Sample Management Solutions segment, specifically for automation systems. |
A main competitor in the Sample Management Solutions segment, particularly for storage, consumables, and services. | |
A main competitor in the Sample Management Solutions segment, particularly for storage, consumables, and services. | |
BGI Genomics Co., Ltd. | A main competitor in the Multiomics segment, particularly in genomic services. |
Eurofins Scientific S.E. | A main competitor in the Multiomics segment, particularly in genomic services. |
GenScript Biotech Corporation | A main competitor in the Multiomics segment, particularly in genomic services. |
Integrated DNA Technologies, Inc. | A main competitor in the Multiomics segment, particularly in genomic services. |
Novogene Co., Ltd. | A main competitor in the Multiomics segment, particularly in genomic services. |
A main competitor in the Multiomics segment, particularly in genomic services. | |
Vestfrost Solutions | A main competitor in the B Medical Systems segment, particularly in temperature-controlled storage and transportation solutions. |
Haier Biomedical | A main competitor in the B Medical Systems segment, particularly in temperature-controlled storage and transportation solutions. |
No recent press releases or 8-K filings found for AZTA.